Sautter-Bihl M L, Bihl H
Dept. of Radiooncology and Nuclear Medicine, Klinikum Karlsruhe, Katharinenhospital, Stuttgart, FRG.
Nuklearmedizin. 1994 Aug;33(4):167-73.
Radioimmunotherapy (RIT) with labeled tumor-associated monoclonal antibodies (MAbs) is a promising concept in oncology, which essentially consists of biological targeting of ionising radiation to tumors. Some encouraging clinical results have been achieved with RIT. However, there are severe problems associated with both understanding the mechanisms and predicting the effectiveness of RIT. This paper reviews the results of some major clinical trials, especially in malignant lymphomas and in some solid tumors. Furthermore, problems with RIT are described such as the significance of dose inhomogeneity and dose-rate effects, the appropriate dose calculation method, the toxicity of RIT and the development of HAMAs. It is suggested that newer technologies including chimeric antibodies, multiple-step targeting protocols, bone marrow transplantation, parallel application of external radiation, heat or bioreductive drugs will enable RIT to make an essential contribution to strategies for combating cancer.
用标记的肿瘤相关单克隆抗体进行放射免疫治疗（RIT）是肿瘤学中一个很有前景的概念，其本质是将电离辐射生物靶向肿瘤。RIT已取得了一些令人鼓舞的临床结果。然而，在理解RIT的机制和预测其有效性方面都存在严重问题。本文综述了一些主要临床试验的结果，特别是在恶性淋巴瘤和某些实体瘤方面的结果。此外，还描述了RIT存在的问题，如剂量不均匀性和剂量率效应的意义、合适的剂量计算方法、RIT的毒性以及人抗鼠抗体（HAMA）的产生。有人提出，包括嵌合抗体、多步靶向方案、骨髓移植、外部辐射、热疗或生物还原药物的并行应用等新技术将使RIT能够为抗癌策略做出重要贡献。
